K-V Pharmaceutical Loses FDA Lawsuit Over Makena Drug #pharma #d

Posted On May 18 2017 by

#kv pharma # K-V Pharmaceutical Loses FDA Lawsuit Over Makena Drug K-V Pharmaceutical Co.’s lawsuit alleging that the U.S. Food and Drug Administration’s actions led to “unlawful competition” involving its Makena drug was dismissed by a federal judge. U.S. District Judge Amy Berman Jackson in Washington today threw out the company’s claims that the FDA caused it “irreparable harm” by refusing to block pharmacies that created a cheaper alternative of the drug used to reduce the risk of pre-term birth in women. “This case is fundamentally an effort to get the court to direct and oversee the FDA’s enforcement activities, …


A – Z Drug List from #pharmaceutical #distributors

Posted On May 18 2017 by

#pharmaceutical information # Drug Index A to Z Multum leaflets provide basic consumer drug information, such as drug descriptions and interactions, details of possible side effects and the effects of missed doses and overdosing, as well as instructions for use. The leaflets are available in English and Spanish. Sourced from leading health information provider Wolters Kluwer Health, Facts Comparisons Integrated MedFacts consumer drug information leaflets provide detailed information on drug indications, contraindications and interactions as well as notes on safety and instructions for use. Facts and Comparisons has been a key source of drug information for pharmacists for more than …


Novartis pharma head leaves as drug maker splits operations #lexicon #pharma

Posted On May 18 2017 by

#novartis pharma # Novartis pharma head leaves as drug maker splits operations Underscoring its increasing emphasis on oncology, Novartis is splitting its prescription drug business into two organizations and hired Paul Hudson, who heads North American operations for AstraZeneca, to lead the pharmaceutical business. The newly created oncology unit, meanwhile, will be run by Bruno Strigini, who already runs the cancer-drug business. The move comes a year after Novartis purchased a portfolio of oncology medicines from GlaxoSmithKline as part of an asset swap. But Novartis is also contending with declining sales of its Gleevec cancer medicine, which has been a …


No Justification for High Drug Prices #galaxy #pharma

Posted On May 17 2017 by

#pharmaceutical companies in new york # The New York Times No Justification for High Drug Prices By THE EDITORIAL BOARD December 19, 2015 There is ample evidence that drug prices have been pushed to astronomical heights for no reason other than the desire of drug makers to maximize profits. Prices in many cases far exceed what’s needed to cover the costs of research and clinical trials, and some companies have found ways to rake in profits even without shouldering the cost of drug development. The two worst offenders are bottom feeders that simply buy companies they believe have underpriced their …


Pill Identifier (Pill Finder Wizard) – Pill Identification Tool Using Drug Pictures, Color, Shape, Number, or Imprint #pharmaceutical #manufacturers #association

Posted On May 17 2017 by

#pharmaceutical drugs # Having trouble identifying prescription, OTC, generic, and brand name pills and capsules? Quickly identify drugs and medications, including pill identifying pictures, using the RxList Pill Identifier Tool. Use the imprint, color, or shape of your pill (one, all or any combination of the fields below) and our Pill Identification Tool (Pill Finder) will show you pictures to review and identify your drug. Need help with the pill finder? Click for instructions. Pill Identification from a Doctor’s Perspective In the emergency room where I work, I sometimes see patients who have either taken the wrong medication or the …


Pharmaceutical industry fights California drug price measure – The Orange County Register #pharmaceutical #contract #manufacturers

Posted On May 16 2017 by

#pharmaceutical companies in orange county # BY PAULINE BARTOLONE. KAISER HEALTH NEWS Drugmakers are waging a fierce campaign against a proposed California law that would require them to justify the costs of their treatments and disclose major price hikes. The bill has widespread support of health care providers, insurers, patients, labor and business groups. But the pharmaceutical industry is behind scathing social media messaging, warning that passage of the bill could lead to shortages of crucial drugs in some parts of the state. The industry is also applying other pressure to change the language of the bill. A state Assembly …


Background on Drug Advertising #leo #pharma #canada

Posted On May 16 2017 by

#pharmaceutical advertising # Background on Drug Advertising The Food and Drug Administration (FDA) protects public health by assuring the safety, effectiveness, and security of a wide range of products, including human prescription drugs. We also advance public health by helping people get the accurate, science-based information they need to use medicines appropriately and improve their health. We serve the public health and welfare in many ways. One way is overseeing the approval and marketing of prescription drugs. Our authority is based on a number of federal laws, including the Federal Food, Drug, and Cosmetic Act. Among other areas, this law …


Pharmacy News – Drug Store News #thaiger #pharma

Posted On May 16 2017 by

#pharmacy news # Pharmacy News Members of participating plans will be able to receive 90-day supplies of their diabetes maintenance meds from more than 10,000 pharmacies including Walgreens and at more than 1,200 independent retail pharmacies. Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. …


Drug company R – D: Nowhere near $1 billion #pharma #rep #jobs

Posted On May 16 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Drug Chemistry MSc – Postgraduate – Newcastle University #pharma #industry #trends

Posted On May 12 2017 by

#drug chemistry # Drug Chemistry MSc Drug Chemistry MSc Profile This course provides advanced training in modern organic and medicinal chemistry from conception to production of novel drugs. It enables you to understand and experience the way modern small molecule medicine is developing. You will gain hands-on experience of working within a medicinal chemistry team during your research project. 100% of Chemistry research impact outstanding or with very considerable impact. The course is suitable if you have a background in the chemical or pharmaceutical sciences. It includes 120 credits of taught modules and a 60 credit practical project. Themes include …